Onychomycosis Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies – Moberg Pharma, Blueberry Therapeutics, Mycovia Pharma, and Others

January 19 16:00 2022
Onychomycosis Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies - Moberg Pharma, Blueberry Therapeutics, Mycovia Pharma, and Others
Delveinsight Business Research LLP
DelveInsight’s “Onychomycosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Onychomycosis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Onychomycosis Market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Onychomycosis: An Overview

Onychomycosis, a fungal infection of the nail, is the most common nail infection worldwide, causing discoloration and thickening of the affected nail plate. Onychomycosis was initially thought to be caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by nondermatophyte molds (NDMs) are more prevalent than thought previously, especially in warmer climates.

Onychomycosis is a common fungal nail infection that has been estimated to account for about half of all nail diseases. Although not life-threatening, fungal nail infections are an important public health concern due to their high prevalence, poor response to therapy, and significant clinical, social, and financial impact.

In Western countries, 80–90% of onychomycosis cases are primarily caused by dermatophytes, with 5–17% due to yeasts and 2–3% due to NDMs. The high prevalence of fungal infections in North America is largely due to the immigration of dermatophytes from other areas of the world, such as West Africa and Southeast Asia.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/onychomycosis-market

Onychomycosis Market Key Facts

  • In 2017, the prevalent population of Onychomycosis in the United States was found to be 35,829,110.

  • As per Delveinsight’s estimates, the total prevalent cases for Onychomycosis were highest in the United States, followed by Japan and France. Spain accounted for the least number of prevalent cases among the 7MM.

  • Adults and the elderly are more likely to suffer from Onychomycosis when compared to children and adolescents.

  • The United States accounted for the largest market size of Onychomycosis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Onychomycosis Market

Onychomycosis market size is expected to increase during the forecast period owing to the increasing prevalent population of Onychomycosis patients in the 7MM, along with the expected entry of new therapies into the market.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Onychomycosis market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.

The report gives a thorough detail of the Onychomycosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Onychomycosis Epidemiology

The epidemiology section covers insights about the historical and current Onychomycosis patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Onychomycosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Onychomycosis market or expected to get launched in the market during the study period. The analysis covers Onychomycosis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Onychomycosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Onychomycosis Therapeutics Analysis

The goals of onychomycosis therapy are to both eliminate the infecting fungal organism and restore the nail to its normal state as it grows. Many potential therapies are being investigated for the management of onychomycosis, and the treatment space will experience significant reconstitution in the coming years.

The key players in the Onychomycosis market include:

  • Moberg Pharma

  • Blueberry Therapeutics

  • Mycovia Pharmaceuticals

And others.

Onychomycosis therapies covered in the report include:

  • MOB-015

  • BB2603

  • VT-1161

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- Onychomycosis Therapeutics Landscape

Table of Content

1. Key Insights

2. Executive Summary 

3. Onychomycosis Competitive Intelligence Analysis

4. Onychomycosis Market Overview at a Glance

5. Onychomycosis Disease Background and Overview

6. Onychomycosis Patient Journey

7. Onychomycosis Epidemiology and Patient Population

8. Onychomycosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Onychomycosis Unmet Needs

10. Key Endpoints of Onychomycosis Treatment

11. Onychomycosis Marketed Products

12. Onychomycosis Emerging Therapies

13. Onychomycosis Seven Major Market Analysis

14. Attribute Analysis

15. Onychomycosis Market Outlook (7 major markets)

16. Onychomycosis Access and Reimbursement Overview

17. KOL Views on the Onychomycosis Market.

18. Onychomycosis Market Drivers

19. Onychomycosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/onychomycosis-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/